supply chain optimization, moving some production between factories and changing how the organization is structured.
The changes are expected to begin this year and be largely finished by the end of 2029.
The company estimates the plan will cost between $700 million and $800 million before taxes, with $600 million to $700 million of that expected to be paid out in cash.
In return, Boston Scientific expects to reduce its annual expenses by about $500 million once the changes are fully in place.
Much of the money saved will be reinvested into growth initiatives, the company said.
Boston is expected to post second-quarter results on July 29 with investor focus on the performance of its heart device portfolio. (Reporting by Padmanabhan Ananthan in Bengaluru)
- Published On Jul 28, 2026 at 11:05 PM IST
Join the community of 2M+ industry professionals.
Subscribe to Newsletter to get latest insights & analysis in your inbox.
All about industry right on your smartphone!
- Download the App and get the Realtime updates and Save your favourite articles.
